National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

HARDBACK
price:$59.95
add to cart

Rights & Permissions

topleft topright

Dietary Supplements: A Framework for Evaluating Safety (2005)
Institute of Medicine (IOM)

Citation Manager

. "4 Categories of Scientific Evidence--Human Information and Data." Dietary Supplements: A Framework for Evaluating Safety. Washington, DC: The National Academies Press, 2005.

Please select a format:

BibTeX EndNote RefMan


Page
139
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


Dietary Supplements: A Framework for Evaluating Safety

pared with modern formulations. In most cases, however, dosing comparisons are so imprecise that they should probably only be attempted when the modern formulation clearly provides doses that may be orders of magnitude higher than traditional doses. For example, consumption of a culinary botanical in small amounts is very different, and thus may have different effects, than consumption of large amounts of the same encapsulated botanical, rendering a safety extrapolation from culinary to supplemental use inappropriate. In summary, if the current level of intake is significantly above what has been traditionally recommended, then the level of concern should be increased.

  • How similar is the current preparation to that used traditionally? Is the preparation a crude preparation, extract, or concentrate; a selected fraction; an isolated compound; or a mixture of these? As discussed above, the toxicity of a substance depends on the amount ingested. The method of preparation will impact the amount and types of chemical compounds ingested, thus potentially impacting an ingredient’s safety. The different methods of preparation are most clearly illustrated with botanicals. Traditionally, many orally ingested medicinal botanicals were administered as crude aqueous extractions of plant parts that were soaked, steeped, or boiled in water. Today’s supplement ingredients are often sold in a different form—as encapsulated dried botanicals, fluid extracts, solid extracts (e.g., capsules or tablets), or foodstuffs containing botanical extracts. The same plant can be used as an extract prepared from dried plant materials (an infusion) or as lyophilized plant made from whole fresh materials.

Whether a botanical with a history of benign use in infusions (teas) manifests new toxic effects when concentrated, lyophilized, or encapsulated will depend on where any toxic components are localized in the plant, their water solubility, their potency, and the likelihood that a person could consume enough of the active ingredients to cause an ill effect. Differences in safety profiles could also be expected for alcoholic versus aqueous extracts of plants with known toxic components. Alcohol and water extract different compounds, so alcohol extracts may contain a higher concentration of toxic compounds than aqueous extracts. Wormwood (Artemisia absinthium), for example, in an aqueous extract contains little thujone (a neurotoxin) (Tegtmeier and Harnischfeger, 1994), but may contain substantial amounts of thujone in alcohol extracts. In summary, if the method of preparation concentrates the bioactive compounds to a degree not known to be consistent with safe historical use, the level of concern should be raised.

In addition to preparations that might result in increased concentration of bioactives in the products ingested, it is also important to note that modern formulations may simply make the same substances more likely to be ingested in excessive amounts, which should raise concern. If a substance

Page
139
Front Matter (R1-R20)
Executive Summary (1-18)
1 Introduction and Background (19-42)
2 Approaches Used by Others and Existing Safety Frameworks (43-84)
3 The Framework (85-125)
4 Categories of Scientific Evidence--Human Information and Data (126-155)
5 Categories of Scientific Evidence--Animal Data (156-174)
6 Categories of Scientific Evidence--Information About Related Substances (175-216)
7 Categories of Scientific Evidence--In Vitro Data (217-234)
8 Interactions (235-246)
9 Vulnerable Groups and Prevalance of Use (247-252)
10 Scientific Principles for Integrating and Evaluating the Available Data (253-268)
11 Applying the Framework: Case Studies Using the Prototype Safety Monographs (269-291)
12 Factors Influencing Use of the Safety Framework (292-296)
13 Findings and Recommendations (297-306)
Appendix A: Existing Frameworks or Systems for Evaluating the Safety of Other Substances (307-315)
Appendix B: Scope of Work and Comments to Initial July 2002 Framework (316-321)
Appendix C: Plant Family Information (322-355)
Appendix D: Chaparral: Prototype Monograph Summary (356-362)
Appendix E: Glucosamine: Prototype Monograph Summary (363-366)
Appendix F: Melatonin: Prototype Monograph Summary (367-371)
Appendix G: Chromium Picolinate: Prototype Monograph Summary (372-375)
Appendix H: Saw Palmetto: Prototype Monograph Summary (376-379)
Appendix I: Shark Cartilage: Prototype Monograph Summary (380-384)
Appendix J: Prototype Focused Monograph: Review of Liver-Related Risks for Chaparral (385-449)
Appendix K: Protoype Focused Monograph: Review of Anti-Androgenic Risks of Saw Palmetto Ingestion by Women (450-477)
Appendix L: Acknowledgements (478-480)
Appendix M: Biographical Sketches of Commitee Members (481-488)
Index (489-506)